Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
Thomas Jefferson University
Children's Oncology Group
Dana-Farber Cancer Institute
FindCure Biosciences (ZhongShan) Co., Ltd.
MedSIR
Baylor College of Medicine
M.D. Anderson Cancer Center
Stanford University
Dana-Farber Cancer Institute
Kaiser Permanente
St. Jude Children's Research Hospital
Canadian Cancer Trials Group
Quantum Surgical
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Kumquat Biosciences Inc.
University of Alabama at Birmingham
Centre Leon Berard
University of Pittsburgh
Baylor College of Medicine
The First Affiliated Hospital with Nanjing Medical University
Indiana University
Ningbo Newbay Technology Development Co., Ltd
AIDS Malignancy Consortium
AIDS Malignancy Consortium
Fudan University
First Affiliated Hospital of Guangxi Medical University
Milton S. Hershey Medical Center
Peking University People's Hospital
AHS Cancer Control Alberta
University of Rochester
Northwestern University
University Health Network, Toronto
Sun Yat-sen University
Fudan University
University of California, San Diego
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
University of Calgary
Peking University
Asan Medical Center
Peking University People's Hospital
National Cancer Institute, Egypt
Medical University of Vienna
NHS Greater Glasgow and Clyde
Tcelltech Inc.
Children's National Research Institute
Institute of Hematology & Blood Diseases Hospital, China
Shaare Zedek Medical Center
Chinese PLA General Hospital